Share
Cardiac Biomarkers Market Size, Share, and Analysis, By Type (Creatine Kinase-MB (CK-MB), Troponin, B-type Natriuretic Peptide (BNP), N-terminal Pro-BNP (NT-proBNP), and Others), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, and Others), By End User (Hospitals, Point of Care Testing, Laboratory Testing, Diagnostic Centers), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034
Cardiac Biomarkers Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 13.8% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 13.9 billion and is projected to reach USD 58.1 billion by the completion of 2034.
Cardiac biomarkers are compounds released into the bloodstream in response to heart damage or stress. They act as distress signals sent out by the heart. Various enzymes, hormones, and proteins, such as cardiac troponins and creatine kinase (CK), are examples of these biomarkers. Troponin is a key cardiac biomarker for detecting heart attacks, while CK-MB can also indicate heart damage. BNP is often used for diagnosing heart failure, and NT-proBNP serves a similar purpose in monitoring and diagnosing heart failure. These biomarkers play a crucial role in diagnosing heart attacks, assessing the severity of heart failure, tracking the effectiveness of treatments, and screening individuals at high risk. They offer advantages including early detection, high specificity and sensitivity, and treatment recommendations.
Cardiac Biomarkers Market is expected to reach USD 58.1 billion during the forecast period. The rising prevalence of heart diseases globally is leading to a higher demand for diagnostic and monitoring tools like cardiac biomarkers. Additionally, with the world's population aging, there is a growing incidence of cardiovascular diseases, highlighting the importance of reliable diagnostic biomarkers. The market is also fueled by the growing understanding of the advantages of early detection and preventive care. Furthermore, the development of improved biomarker testing technologies that are more sensitive and faster is expected to drive market growth. Increased investment in cutting-edge diagnostic technology and personalized healthcare further contributes to the expansion of the market.
Source: Fatpos Global
Cardiac Biomarkers Market is segmented based on Type into Creatine Kinase-MB (CK-MB), Troponin, B-type Natriuretic Peptide (BNP), N-terminal Pro-BNP (NT-proBNP), and Others. The Troponin segment is anticipated to lead the market due to its high specificity and sensitivity. Troponin ensures accurate detection of heart attacks and distinguishes them from other heart conditions. It is widely recognized as the most effective way to diagnose heart attacks and is frequently used in emergency rooms and medical centers. Additionally, troponin levels can be observed soon after heart damage and may remain elevated for several days, enabling timely and accurate detection of myocardial injury, which is crucial for prompt medical treatment and improved patient outcomes. There is also a well-established infrastructure and protocols for troponin testing, ensuring widespread availability and integration into standard practices.
Cardiac Biomarkers Market is classified based on Application into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, and Others. The Acute Coronary Syndrome segment will dominate the industry due to its high incidence. ACS, including heart attacks and unstable angina, is a leading cause of emergency visits and hospital stays, emphasizing the importance of fast and precise diagnosis for prompt treatment. The rise in urbanization and sedentary lifestyles is contributing to the spread of the disease. Rapid diagnosis and intervention in ACS are crucial for better outcomes, highlighting the importance of biomarker testing. Furthermore, biomarkers, particularly troponin, have shown great sensitivity and specificity in identifying myocardial damage related to ACS.
Source: Fatpos Global
Increasing Incidence of Heart Conditions are Critical to Boosting the Adoption of Cardiac Biomarkers
The rising prevalence of heart conditions is driving substantial growth in the cardiac biomarkers market. This increase in demand for diagnosis and monitoring is fueled by a greater emphasis on early detection and preventive care. There is a growing need for precise diagnostic tools like cardiac biomarkers as cases of acute coronary syndrome, heart attacks, and heart failure continue to rise. These biomarkers play a crucial role in monitoring disease progression and informing treatment decisions. Additionally, ongoing advancements in testing methods are being driven by the need for quick and accurate diagnosis to prevent issues and improve outcomes. Increased investment in advanced diagnostic equipment in the healthcare sector is also contributing to the development of novel tests, further driving market growth
Advancements in Cardiac Biomarker Technologies Will Aid the Market
Market growth is significantly propelled by advances in cardiac biomarker technologies. Improved precision and reliability of novel tests lead to greater detection capabilities, resulting in increased clinical use and regular monitoring. Faster testing procedures lead to quicker outcomes, which are crucial for prompt identification and care, especially in urgent situations. Innovations have also resulted in the identification of new biomarkers, increasing diagnostic options and addressing a broader range of heart conditions. Additionally, incorporating automation and other diagnostic tools into workflows improves efficiency and attracts healthcare providers. These factors enhance diagnosis, efficiency, and personalized care, contributing to the expansion of the cardiac biomarkers market..
High Costs of Cardiac Biomarker Tests Can Limit the Growth of the Cardiac Biomarkers Market
High costs of cardiac biomarker tests are a significant barrier to the growth of the cardiac biomarkers market. Financial barriers, especially in low-resource settings or among underinsured patients, limit accessibility and can cause delays in diagnosis and treatment. Additionally, the escalating healthcare costs due to expensive tests strain hospital budgets, leading to a preference for cheaper diagnostic methods. The perceived benefits of these costly tests may not always justify their high expenses, prompting a shift toward more affordable alternatives. Insurance coverage issues also contribute to limited access, as not all policies fully cover advanced tests, leaving patients to bear the costs out of pocket, which significantly restricts market growth.
Cardiac Biomarkers Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The North American region is anticipated to dominate the Cardiac Biomarkers Market as the region area has a robust healthcare system with advanced diagnostic facilities and widespread use of cardiac biomarkers. Also, there is a high occurrence of cardiovascular diseases in the area, leading to a need for efficient diagnostic equipment. Many top companies in the cardiac biomarkers sector are based in North America, helping to drive market expansion. Furthermore, the investment in medical research and development in this region leads to innovation in biomarker technologies, with support from a regulatory environment that helps approve and implement new diagnostic advancements.
Source: Fatpos Global
COVID-19 pandemic had a dual impact on the Cardiac Biomarkers Market. Initially, the pandemic led to interruptions in the supply chain, impacting the manufacturing and distribution of cardiac biomarker testing kits and reagents. Testing materials shortages and logistic delays affected the availability of these tests, causing challenges for healthcare providers. However, the pandemic highlighted the heart-related issues linked to severe COVID-19 cases, like myocarditis and acute coronary syndrome, leading to an increased need for cardiac biomarkers for diagnosis and treatment. The pandemic rapidly boosted the utilization of telemedicine and remote monitoring, which also included cardiac biomarker tests conducted at home. This resulted in fresh concepts in remote diagnostics and broadened the market for at-home testing and telehealth services. Furthermore, the pandemic accelerated the investigation into the connection between cardiac biomarkers and COVID-19, leading to new findings and possible advancements in biomarker creation.
|
ATTRIBUTE |
DETAILS |
|
Study Period |
2018-2034 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2034 |
|
Historical Period |
2019-2022 |
|
Growth Rate |
CAGR of 13.8% from 2024-2034 |
|
Unit |
Value (USD Billion) |
|
Segmentation |
Main Segments List |
|
By Type |
|
|
By Application |
|
|
By End User |
|
|
By Region |
|
Cardiac Biomarkers Market size was valued at USD 13.9 billion in 2023 and is projected to reach the value of USD 58.1 billion in 2034, exhibiting a CAGR of 13.8% during the forecast period.
The Cardiac Biomarkers Market involves the industry focused on diagnostic tests and technologies used to detect and monitor heart-related conditions.
The Troponin segment and the Acute Coronary Syndrome segment accounted for the largest Cardiac Biomarkers Market share.
Key players in the Cardiac Biomarkers Market include Abbott Laboratories, Becton, Dickinson and Company, Luminex Corporation, Roche Diagnostics, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., bioMérieux SA, Fujirebio, Beckman Coulter, ACON Laboratories, Inc., Ortho Clinical Diagnostics, Siemens Healthineers, Randox Laboratories Ltd., Trinity Biotech, Thermo Fisher Scientific Inc., and Other Prominent Players.
The increasing incidence of heart conditions and advancements in cardiac biomarkers technologies are the factors driving the cardiac biomarkers market.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
